By Counterforce Health Team in Bavencio (avelumab) —

How to Get Bavencio (Avelumab) Covered by Aetna CVS Health in Pennsylvania: Prior Authorization Guide, ICD-10 Codes, and Appeals Process

Answer Box: Getting Bavencio Covered by Aetna CVS Health in Pennsylvania

Aetna CVS Health requires prior authorization for Bavencio (avelumab) in Pennsylvania. The fastest path to approval: 1) Verify your oncologist submits the PA request with confirmed ICD-10 diagnosis codes (C4A for Merkel cell carcinoma, C67 for urothelial carcinoma) and documentation of prior platinum chemotherapy failure. 2) Use HCPCS code J9023 for billing (10 mg units). 3) If denied, file internal appeal within 180 days, then Pennsylvania's external review within 4 months—which overturns ~50% of denials. Start by calling Aetna member services at the number on your insurance card to confirm your specific plan's formulary status.

Table of Contents

Coding Basics: Medical vs. Pharmacy Benefit Paths

Bavencio (avelumab) is typically covered under the medical benefit rather than pharmacy benefit because it's administered as an IV infusion in clinical settings. This means:

  • Medical benefit: Uses HCPCS J-codes for the drug plus separate CPT codes for administration
  • Site of care matters: Aetna often requires justification for hospital outpatient vs. clinic infusion
  • Prior authorization required: Specialty oncology medications like Bavencio need pre-approval
Tip: Contact your clinic's billing department early—they'll need to coordinate both drug approval and infusion site authorization.

ICD-10 Diagnosis Codes for Bavencio

Primary Diagnosis Codes

For Merkel Cell Carcinoma:

  • C4A: Merkel cell carcinoma (primary code family)
  • Document as "neuroendocrine skin cancer" in clinical notes

For Urothelial Carcinoma:

  • C67: Malignant neoplasm of bladder
    • C67.0: Trigone of bladder
    • C67.1: Dome of bladder
    • C67.9: Bladder, unspecified (use when location not documented)

Documentation Requirements for ICD-10 Support

Your oncologist's notes should include:

  • Histopathology confirmation via biopsy results
  • Staging information (TNM classification)
  • Prior treatment history including platinum-based chemotherapy
  • Current disease status (maintenance therapy setting for urothelial carcinoma)
Important: Use active cancer codes (C4A, C67) during treatment, not history codes (Z85.xx) which are for surveillance only.

HCPCS, J-Codes, and NDC Information

Billing Codes for Bavencio

Code Type Code Description Units
HCPCS J-Code J9023 Injection, avelumab, 10 mg 1 unit = 10 mg
NDC 44087-3535-01 Bavencio 200 mg/10 mL vial Per vial

Dosing and Unit Calculations

Standard dose: 800 mg IV every 14 days

  • Billing units: 80 units of J9023 per dose (800 mg ÷ 10 mg = 80 units)
  • Cycle: Repeat every 2 weeks until disease progression

Administration Codes

Bill separately for the infusion service:

  • 96413: Chemotherapy administration, IV infusion, up to 1 hour
  • 96415: Each additional hour (if needed)
  • 96416: Initiation of prolonged infusion

Prior Authorization Request Anatomy

Essential Components of a Clean PA Request

Patient Information:

  • Insurance ID and group number
  • Complete diagnosis with ICD-10 codes
  • Prescribing oncologist's NPI number

Clinical Documentation:

  • Pathology report confirming cancer type
  • Imaging showing disease status
  • Prior platinum chemotherapy records (dates, doses, response)
  • Performance status documentation

Treatment Plan:

  • Bavencio 800 mg IV every 14 days
  • Duration of treatment planned
  • Site of care justification
Clinician Corner: Medical necessity letters should explicitly state "platinum-based chemotherapy failure" with specific dates and response measurements (RECIST criteria preferred).

Common Coding Pitfalls to Avoid

Unit Conversion Errors

  • Wrong: Billing 800 units for 800 mg dose
  • Right: Billing 80 units (800 mg ÷ 10 mg per unit)

Mismatched ICD-10 Codes

  • Wrong: Using Z85.51 (personal history) during active treatment
  • Right: Using C4A or C67 for ongoing cancer treatment

Missing Documentation

  • Incomplete: "Patient needs Bavencio"
  • Complete: "Patient with metastatic Merkel cell carcinoma (C4A.9) requires avelumab maintenance therapy following documented progression on carboplatin/etoposide regimen (dates: X-Y)"

Site of Care Issues

  • Document why clinic vs. hospital outpatient is medically appropriate
  • Include any infusion reaction history or monitoring needs

Verifying Codes with Aetna CVS Health

Pre-Submission Verification Steps

  1. Check formulary status: Use Aetna's provider portal or call member services
  2. Confirm PA requirements: Review current precertification lists
  3. Verify coverage tier: Specialty medications may have higher copays
  4. Site of care review: Confirm if outpatient hospital requires separate authorization

Real-Time Verification Tools

  • Availity portal: For real-time eligibility and benefits
  • CVS Caremark: For specialty pharmacy coordination
  • Member services: Call number on insurance card for plan-specific details

Pre-Submission Audit Checklist

Before submitting your PA request, verify:

✓ Patient eligibility confirmed (active Aetna coverage)
✓ Correct ICD-10 codes (C4A for Merkel cell, C67 for urothelial)
✓ Accurate HCPCS units (80 units of J9023 for 800 mg dose)
✓ Prior platinum therapy documented with dates and outcomes
✓ Prescriber is oncology specialist (may be required)
✓ Site of care justified (clinic vs. hospital outpatient)
✓ All supporting documents attached (pathology, imaging, treatment history)

Appeals Process in Pennsylvania

Internal Appeals with Aetna CVS Health

Timeline: 180 days from denial letter date
Method: Submit via Aetna provider portal or member services
Required documents:

  • Original denial letter
  • Medical necessity letter from oncologist
  • Updated clinical documentation
  • Peer-reviewed literature supporting off-label use (if applicable)

Pennsylvania External Review Process

Pennsylvania's Independent External Review Program, launched in 2024, provides a powerful second-level appeal option.

Eligibility: Must complete Aetna's internal appeal first
Timeline: 4 months from final internal denial to request external review
Success rate: Approximately 50% of appeals are overturned
Process: Submit online at PA Insurance Department

Expedited Appeals

For urgent situations where delay could harm health:

  • Internal expedited: 72 hours for standard cases
  • External expedited: 72 hours with physician certification
  • Required: Physician must certify that delay poses serious health risk

When battling insurance denials feels overwhelming, Counterforce Health helps patients and clinicians turn denials into targeted, evidence-backed appeals. The platform analyzes denial letters and plan policies to create point-by-point rebuttals aligned with the insurer's own rules, pulling the right clinical evidence and citations to strengthen your case.

Cost Assistance Options

Manufacturer Support Programs

Check with EMD Serono/Pfizer for patient assistance programs (verify current availability with your oncology team).

Foundation Grants

  • National Organization for Rare Disorders (NORD)
  • Patient Access Network Foundation
  • Cancer Care Co-Payment Assistance

State Resources

Pennsylvania residents may qualify for additional support through state pharmaceutical assistance programs.

FAQ

How long does Aetna CVS Health prior authorization take for Bavencio in Pennsylvania?
Standard PA decisions typically take 30-45 days, though >95% of eligible requests are approved within 24 hours according to Aetna's data. Expedited reviews for urgent cases are completed within 72 hours.

What if Bavencio is non-formulary on my Aetna plan?
You can request a formulary exception with documentation that alternatives are inappropriate or have failed. Your oncologist will need to provide medical necessity justification.

Can I request an expedited appeal if my cancer is progressing?
Yes, both internal appeals (72 hours) and Pennsylvania external reviews (72 hours) offer expedited options when delay poses serious health risks. Your physician must certify the urgency.

Does step therapy apply to Bavencio if I've already failed platinum chemotherapy outside Pennsylvania?
Treatment history from other states should count toward step therapy requirements. Ensure your oncologist documents all prior therapies with dates and outcomes in the PA request.

What happens if Pennsylvania's external review overturns Aetna's denial?
The decision is binding—Aetna must provide coverage immediately, including retroactive coverage if you paid out-of-pocket during the appeal process.

How do I track my PA status with Aetna CVS Health?
Use Aetna's provider portal for real-time status updates, or call the member services number on your insurance card. Your oncology clinic can also check status through their provider systems.

From our advocates: In our experience working with Pennsylvania patients, the most successful appeals include clear documentation of platinum chemotherapy failure with specific dates and imaging results. One approach that often works is having the oncologist explicitly state in their letter: "Delay in accessing FDA-approved avelumab maintenance therapy following platinum failure poses immediate risk of disease progression and compromised survival outcomes." This language helps reviewers understand the urgency while staying within evidence-based medicine.

Need help navigating complex appeals? Counterforce Health specializes in turning insurance denials into successful approvals by identifying the specific denial basis and crafting targeted rebuttals with the right clinical evidence and payer-specific documentation requirements.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual plan terms and medical circumstances. Always consult with your healthcare provider and insurance company for personalized guidance. For additional help with Pennsylvania health insurance issues, contact the Pennsylvania Insurance Department's consumer services.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.